The UK and US have hammered out a key trade agreement that will maintain no duties on UK pharmaceutical shipments being sold in the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to increase spending on drugs through the NHS. This pledge ensures that tariffs on these key exports will be held at zero for a timeframe of 36 months.
This agreement is in response to recent warnings to significantly raise duties on branded drug imports, with increases discussed reaching 100%.
"This agreement between the UK bolsters the global environment for innovative medicines and establishes much-needed fairness to U.S.–U.K. drug exports," a release declared.
Trade Impact
Drugs are one of the Britain's most significant goods shipped to the United States, which is by far the largest destination for large companies like GSK and AstraZeneca.
Statistics show that in the one-year period prior to last September, the UK sold medicines totaling over eleven billion pounds to the US. This value represented nearly one-fifth of British export trade in that period.
"This deal secures employment, increases investment and facilitates the UK to establish itself as a international leader for life sciences," a minister remarked.
Specific NHS Changes
The deal includes several notable changes from the United Kingdom:
- Price Threshold Increase: The UK will lift the cost ceiling at which it judges new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a aim to double total NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The amount drug companies must refund to the NHS to prevent overspending will be restricted at fifteen percent. Last year, repayments were more than twenty percent.
Broader Context
The pact comes amid a ongoing row between the sector and the UK government over medicine costs and approval rates.
These tensions were exacerbated by claims that American patients were paying significantly more for the same drugs than patients in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or cancelled, while substantial expansions have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS needed to spend more on medicines, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the past decade.
